ID   LYRA_STAA8              Reviewed;         419 AA.
AC   Q2FVT1;
DT   06-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2006, sequence version 1.
DT   25-MAY-2022, entry version 78.
DE   RecName: Full=Lysostaphin resistance protein A;
GN   Name=lyrA; OrderedLocusNames=SAOUHSC_02611;
OS   Staphylococcus aureus (strain NCTC 8325 / PS 47).
OC   Bacteria; Firmicutes; Bacilli; Bacillales; Staphylococcaceae;
OC   Staphylococcus.
OX   NCBI_TaxID=93061;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=NCTC 8325 / PS 47;
RA   Gillaspy A.F., Worrell V., Orvis J., Roe B.A., Dyer D.W., Iandolo J.J.;
RT   "The Staphylococcus aureus NCTC 8325 genome.";
RL   (In) Fischetti V., Novick R., Ferretti J., Portnoy D., Rood J. (eds.);
RL   Gram positive pathogens, 2nd edition, pp.381-412, ASM Press, Washington
RL   D.C. (2006).
RN   [2]
RP   DISRUPTION PHENOTYPE, AND MUTAGENESIS OF GLU-135; ARG-139; ARG-196 AND
RP   HIS-210.
RX   PubMed=16923896; DOI=10.1128/jb.00457-06;
RA   Gruendling A., Missiakas D.M., Schneewind O.;
RT   "Staphylococcus aureus mutants with increased lysostaphin resistance.";
RL   J. Bacteriol. 188:6286-6297(2006).
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- DISRUPTION PHENOTYPE: Cells show an increase in lysostaphin resistance,
CC       without a concomitant decrease in beta-lactam resistance. The mutants
CC       also show minor defects in peptidoglycan and pentaglycine cross bridge
CC       structure. {ECO:0000269|PubMed:16923896}.
CC   -!- SIMILARITY: Belongs to the LyrA family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000253; ABD31621.1; -; Genomic_DNA.
DR   RefSeq; WP_000794442.1; NZ_LS483365.1.
DR   RefSeq; YP_501072.1; NC_007795.1.
DR   PDB; 6U0O; X-ray; 2.60 A; A=1-256.
DR   PDBsum; 6U0O; -.
DR   AlphaFoldDB; Q2FVT1; -.
DR   SMR; Q2FVT1; -.
DR   STRING; 1280.SAXN108_2585; -.
DR   EnsemblBacteria; ABD31621; ABD31621; SAOUHSC_02611.
DR   GeneID; 3921389; -.
DR   KEGG; sao:SAOUHSC_02611; -.
DR   PATRIC; fig|93061.5.peg.2359; -.
DR   eggNOG; COG1266; Bacteria.
DR   HOGENOM; CLU_046135_0_0_9; -.
DR   OMA; MAFFAEF; -.
DR   PHI-base; PHI:7997; -.
DR   PRO; PR:Q2FVT1; -.
DR   Proteomes; UP000008816; Chromosome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..419
FT                   /note="Lysostaphin resistance protein A"
FT                   /id="PRO_0000274827"
FT   TRANSMEM        9..29
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        41..61
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        84..104
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        118..138
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        153..173
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        175..195
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        202..222
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        231..251
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          273..419
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        273..295
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        296..318
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        319..357
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        358..372
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        379..419
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MUTAGEN         135
FT                   /note="E->A: Does not affect lysostaphin resistance."
FT                   /evidence="ECO:0000269|PubMed:16923896"
FT   MUTAGEN         139
FT                   /note="R->A: Does not affect lysostaphin resistance."
FT                   /evidence="ECO:0000269|PubMed:16923896"
FT   MUTAGEN         196
FT                   /note="R->A: Does not affect lysostaphin resistance."
FT                   /evidence="ECO:0000269|PubMed:16923896"
FT   MUTAGEN         210
FT                   /note="H->A: Does not affect lysostaphin resistance."
FT                   /evidence="ECO:0000269|PubMed:16923896"
SQ   SEQUENCE   419 AA;  46785 MW;  D109375573B11E25 CRC64;
     MKNNKISGFQ WAMTIFVFFV ITMALSIMLR DFQSIIGVKH FIFEVTDLAP LIAAIICILV
     FKYKKVQLAG LKFSISLKVI ERLLLALILP LIILIIGMYS FNTFADSFIL LQSTGLSVPI
     THILIGHILM AFVVEFGFRS YLQNIVETKM NTFFASIVVG LMYSVFSANT TYGTEFAAYN
     FLYTFSFSMI LGELIRATKG RTIYIATTFH ASMTFGLIFL FSEEIGDLFS IKVIAISTAI
     VAVGYIGLSL IIRGIAYLTT RRNLEELEPN NYLDHVNDDE ETNHTEAEKS SSNIKDAEKT
     GVATASTVGV AKNDTENTVA DEPSIHEGTE KTEPQHHIGN QTESNHDEDH DITSESVESA
     ESVKQAPQSD DLTNDSNEDE IEQSLKEPAT YKEDRRSSVV IDAEKHIEKT EEQSSDKNK